# CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

> **NCT07461831** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Tongren Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Large B-Cell Lymphoma (LBCL)

## Interventions

- **DRUG:** CD19/CD22 bispecific CAR-T cells

## Key facts

- **NCT ID:** NCT07461831
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-01
- **Primary completion:** 2026-04-18
- **Final completion:** 2027-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07461831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07461831, "CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07461831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*